Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service lumbar fusion cases in Pennsylvania: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (239 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 97 | 3,993 | 47% |
| 2020 | 79 | 3,482 | 49% |
| 2021 | 79 | 3,780 | 51% |
| 2022 | 82 | 3,469 | 53% |
| 2023 | 92 | 3,544 | 56% |
| 2024 | 89 | 3,644 | 58% |
| 2025 from claims | – | 3,693 3,389–3,907 | 59% |
| 2026 forecast | – | 3,758 3,306–4,336 | 59% |
| 2027 forecast | – | 3,775 3,227–4,498 | 59% |
| 2028 forecast | – | 3,791 3,163–4,642 | 60% |
| 2029 forecast | – | 3,807 3,109–4,774 | 60% |
| 2030 forecast | – | 3,822 3,062–4,898 | 61% |
Posterolateral, interbody, and anterior lumbar fusion with instrumentation. Professional codes (what the surgeon bills): CPT 22612, 22630, 22633, 22558; the hospital bills MS-DRG 453, 454, 455, 459, 460, 402, 426, 427, 428, 447, 448, 450, 451, 523, 524, 525.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 28% of the cases CMS names in Pennsylvania; 50 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 69% inpatient hospital, 28% hospital outpatient, 3% surgery center. The share outside the hospital has moved +3 pts since 2019, so more of this market is decided in surgery centers and offices each year.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 96 | 3,407−0.3%/yr | −0.3%/yr | 1.8 | 1% | 4,050 in 2030+2.9%/yr |
| Massachusetts | 61 | 2,186+0.3%/yr | +0.3%/yr | 2.3 | 0% | 2,550 in 2030+2.6%/yr |
| New Jersey | 40 | 1,764+6.8%/yr | +6.8%/yr | 1.6 | 11% | 2,120 in 2030+3.1%/yr |
| Connecticut | 25 | 965+0.5%/yr | +0.5%/yr | 2.8 | 0% | 1,000 in 2030+0.5%/yr |
| New Hampshire | 6 | 324−6.1%/yr | −6.1%/yr | 1.4 | 0% | 500 in 2030+7.7%/yr |
| Rhode Island | 8 | 294−2.1%/yr | −2.1%/yr | 3.1 | 0% | 460 in 2030+7.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 95 | 4,474−6.6%/yr | −6.6%/yr | 3.21.3× | 2% | 4,650 in 2030+0.6%/yr |
| Cervical fusion & disc arthroplasty | 23 | 1,803−4.6%/yr | −4.6%/yr | 1.31.3× | 0% | 1,920 in 2030+1%/yr |
| Kyphoplasty & vertebroplasty | 13 | 1,396−2.9%/yr | −2.9%/yr | 1.01.3× | 12% | 1,330 in 2030−0.7%/yr |
| SI joint fusion | 3 | 212+10%/yr | +10%/yr | 0.11.4× | 16% | 590 in 2030+19%/yr |
Lumbar fusion in every state, and its device makers · Every procedure market in Pennsylvania · Every state · Compare with New York
Medtronic leads with 30% of company spending on these surgeons in 2025, +18 pts on 2024.
In 2025, 26 companies reported engagement with Pennsylvania’s surgeons worth $952K in consulting, speaking, meals and travel tied to these products, about $11K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 87 clearances and approvals in the category, 12 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.